Researchers have made a groundbreaking discovery by transforming probiotic bacteria into tiny drug factories that can target pancreatic cancer cells. This novel approach involves engineering these bacteria to carry an immune-stimulating treatment directly into pancreatic tumors.
Key Insights
The engineered probiotic bacteria have the ability to infiltrate pancreatic tumors and stimulate cancer-fighting immune cells, leading to slowed tumor growth. Moreover, when combined with conventional treatments such as chemotherapy, radiotherapy, or immunotherapy, the outcomes are significantly improved. Notably, the bacteria tend to accumulate preferentially inside the tumors, which helps in reducing side effects and enhancing the efficacy of the treatment.
